NCT01095627已完成不适用
Characterization of Aerosol Generation and Transport in the Human Lung of Subjects With Mild Intermittent Allergic Asthma Before and After Methacholine Challenge
Fraunhofer-Institute of Toxicology and Experimental Medicine0 个研究点目标入组 10 人开始时间: 2010年3月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 主要终点
- Exhaled breath analysis
研究概览
简要总结
This study is aiming at evaluating whether the number and size of exhaled particles changes during the increase and decrease of bronchial constriction in subjects with mild intermittent asthma.
详细描述
Particle emission demonstrates high reproducibility within subjects while between-subject-variability is large. Methacholine challenge in subjects with mild intermittent asthma will provide data from repetitive measurements in the same subject with variable airflow obstruction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects, aged 18 to 65 years.
- •Physician diagnosis of mild intermittent allergic asthma (GINA I according to GINA guidelines9).
- •Normal lung function parameters at baseline (FEV1 > 80 % of predicted)
- •Non smoker or smokers with a history of less than 10 pack years with no smoking in the last 12 months.
- •Able and willing to give written informed consent
- •Women will be considered for inclusion if they are:
- •not pregnant, as confirmed by pregnancy test, and not nursing of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal, with documented proof of hysterectomy or tubal ligation, or meet clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit) of childbearing potential and using a highly effective method of contraception during the entire study (vasectomized partner, sexual abstinence - the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to the study until at least 72 hours after the end of the study -, implants, injectables, combined oral contraceptives, hormonal IUDs, or double-barrier methods, i.e. any double combination of IUD, condom with spermicidal gel, diaphragm, sponge, and cervical cap)
- •Available to complete all study measurements
排除标准
- •History of lower respiratory tract infection four weeks prior to the informed consent visit.
- •Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).
- •Regular intake of any prescribed or over the counter medication. Exceptions include paracetamol for pain relief, oral contraceptive medication, hormonal replacement therapy, dietary and vitamin supplements, and short acting beta mimetics (SABA) on as needed basis.
- •Use of anti-inflammatory medication including systemic or inhaled corticosteroid within the last four weeks.
- •Any history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures.
- •Conditions or factors, which would make the subject unlikely to be able to undergo methacholine challenge.
- •Conditions which provide a contraindication for methacholine challenge testing such as uncontrolled arterial hypertension, known aortic aneurysm, myocardial infarction or stroke within three months prior to study, current use of cholinesterase inhibitor medication.
- •Inability to perform acceptable-quality spirometry.
- •History of drug or alcohol abuse.
- •Participation in another clinical trial 30 days prior to enrolment.
- •Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study.
- •Risk of non-compliance with study procedures.
结局指标
主要结局
Exhaled breath analysis
时间窗: Within one day
In ten subjects with mild intermittent allergic asthma particles in exhaled breath will be analyzed for their number and size in a time dependent manner before and after induction of bronchial obstruction by methacholine challenge.
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Characterization of Aerosol Generation and Transport in the Human Lung of Subjects With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseNCT01088633Fraunhofer-Institute of Toxicology and Experimental Medicine50
已完成
不适用
Quantification of Exhaled Particles to Identify Airborne Transmission Risks of COVID-19HealthyNCT04771585Fraunhofer-Institute of Toxicology and Experimental Medicine30
已完成
不适用
High-Flow Aerosol Generation StudyOxygen Therapy Heart SurgeryNCT05384275Papworth Hospital NHS Foundation Trust61
已完成
不适用
Aerosol Particle From EGD in Patients With and Without Head Box in COVID-19 EraEGDCovid19Aerosol DiseaseHead BoxNCT04981535King Chulalongkorn Memorial Hospital190
已完成
不适用
Determination of aerosol particle number and aerosol particle size distribution in exhaled air of healthy children as well as children with respiratory tract infections, especially also children with and after SARS-CoV2 infection/Covid-19.07.1DRKS00028539Ina und Gerhard Scheuch Stiftung für Aerosol- Medizin- Forschung250